COMPASS Pathways plc — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report. COMPASS Pathways is a clinical-stage biotechnology company developing COMP360 psilocybin treatment with psychological support, led by its treatment-resistant depression (TRD) program. It has no approved products and has generated no revenue.
Financial performance and liquidity
| Metric (USD millions, except per-share data) | FY2023 | FY2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $87.5 | $65.1 |
| General and administrative expense | $49.4 | $45.4 |
| Total operating expenses / operating loss | $136.9 | $110.4 |
| Net loss | $118.5 | $91.5 |
| Net loss per share, basic and diluted | $2.32 | $2.16 |
| Net cash used in operating activities | $97.4 | $105.5 |
| Cash and cash equivalents at year-end | $220.2 | $143.2 |
Gross margin is not applicable because the company has no product revenue. R&D spending rose $22.5 million, mainly from increased clinical-trial costs and research staffing. G&A rose $4.1 million; lower legal and advisory fees partly offset higher share-based compensation, facilities, banking and Center of Excellence costs.
FY2023 other income included a $12.9 million UK R&D tax-credit benefit, down from $14.4 million, and $3.7 million in foreign-exchange gains. Interest expense was $2.2 million following the Hercules loan. Cash used in investing activities was $0.1 million; financing provided $173.8 million, primarily from the PIPE, ATM sales and debt proceeds. The accumulated deficit was $379.6 million.
At year-end, current assets were $261.3 million and current liabilities $19.6 million. Long-term debt had a carrying value of $28.8 million. The $30 million Hercules term loan bears interest at the greater of prime plus 1.50% or 9.75%, plus 1.40% PIK interest; its reported effective rate was 15.8%. It matures July 1, 2027. Additional $10 million tranches are conditional, and a $22.5 million minimum-cash covenant begins July 1, 2024, subject to stated conditions. The company reported covenant compliance at year-end.
Material changes and developments
- Net loss widened by $27.0 million year over year, while operating cash use decreased by $8.1 million.
- COMPASS raised $116.8 million net in its August 2023 PIPE, issuing 16.1 million ADSs and warrants for up to 16.1 million more at $9.93 per ADS. Full cash exercise could provide approximately $159.6 million gross, but is not assured and would dilute shareholders.
- It drew $30 million under the Hercules facility and raised $28.1 million net through its ATM in 2023.
- Management estimates year-end cash, together with first-quarter 2024 net proceeds, will fund operating and capital needs into late 2025; this depends on assumptions and spending, financing and trial developments.
Outlook, clinical progress and key risks
- TRD Phase 3: COMP005 tests a single 25 mg dose against placebo (255 participants); topline results were expected in Q4 2024. COMP006 tests repeat dosing across 25 mg, 10 mg and 1 mg arms (568 participants); topline results were expected by mid-2025. Both use change in MADRS score at week 6 as the primary endpoint. These are management timelines, not guarantees.
- Other studies: The company expected PTSD Phase 2 safety and efficacy data in spring 2024. Its 60-participant anorexia nervosa Phase 2 trial experienced recruitment and screening delays, prompting protocol changes. An MDD Phase 2 study was also underway.
- Prior evidence, not FY2023 Phase 3 results: The completed Phase 2b TRD study reported a statistically significant week-3 MADRS difference for 25 mg versus 1 mg; 29.1% of the 25 mg group was in remission at week 3. Serious adverse events included suicidal ideation, behavior and intentional self-injury. Phase 3 outcomes may differ.
- COMP360 contains controlled substances. U.S. commercialization would require FDA approval and DEA scheduling action; UK and other jurisdictions have separate control and licensing requirements. Regulatory feedback, trial design, safety findings, enrollment, therapist availability, manufacturing and supply could delay development or prevent approval.
- Commercial success also depends on building treatment-site and therapist capacity, payer coverage and reimbursement, and acceptance of a treatment requiring psychological support. The company relies on third parties for manufacturing and clinical execution and currently relies on a single API supplier, although it identified potential backup suppliers.
- Management disclosed substantial ongoing losses and a need for additional funding beyond its stated runway. The PIPE warrants may not be exercised for cash; equity financing could dilute investors, while debt carries covenants and repayment risk. Greenbrook TMS, a research collaborator, has disclosed substantial doubt about its ability to continue as a going concern.
- The UK R&D tax-credit benefit is material and depends on qualifying-cost judgments. The auditors identified it as a critical audit matter; the company said its 2022 credit was approved for payment in January 2024 but had not yet been received as of the filing’s reporting date.
Investor verification priorities
- Check actual COMP005 and COMP006 enrollment, protocol status, FDA feedback and eventual results against the timelines stated in this February 2024 filing.
- Track cash burn, post-year-end financing, warrant exercises and dilution, and whether the company can maintain Hercules covenant compliance and its late-2025 runway estimate.
- Verify receipt and eligibility of UK R&D tax-credit claims, including the outstanding 2022 credit, and assess sensitivity to changes in relief rules.
- Monitor DEA scheduling and other regulatory requirements, trial safety and recruitment, and the availability of qualified therapists and manufacturing supply.
- Assess whether potential treatment sites and payers can support a scalable, reimbursed delivery model; review Greenbrook’s financial condition and ability to perform its collaboration obligations.
Filing controls: The independent auditor gave an unqualified opinion on the consolidated financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2023; the auditor did not provide an internal-control attestation.